Malajzia - angličtina - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

luen wah medical co. sdn. bhd. - favipiravir -

Južná Afrika - angličtina - South African Health Products Regulatory Authority (SAHPRA)

glaxosmithkline south africa (pty) limited - powder - see ingredients - each blister contains zanamivir 5,0 mg

Kanada - angličtina - Health Canada

hoffmann-la roche limited - baloxavir marboxil - tablet - 80mg - baloxavir marboxil 80mg

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - baloxavir marboxil, quantity: 40 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; microcrystalline cellulose; povidone; sodium stearylfumarate; purified talc; hypromellose; titanium dioxide - treatment of influenza,xofluza is indicated for the treatment of uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours and who are:,? otherwise healthy, or,? at high risk of developing influenza complications.,prophylaxis of influenza,xofluza is indicated for the post-exposure prophylaxis of influenza in patients aged 12 years of age and older following contact with an individual who has confirmed influenza.,vaccination is the preferred method of routine prophylaxis against infection with influenza virus.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - baloxavir marboxil, quantity: 20 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; microcrystalline cellulose; povidone; sodium stearylfumarate; purified talc; hypromellose; titanium dioxide - treatment of influenza,xofluza is indicated for the treatment of uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours and who are:,? otherwise healthy, or,? at high risk of developing influenza complications.,prophylaxis of influenza,xofluza is indicated for the post-exposure prophylaxis of influenza in patients aged 12 years of age and older following contact with an individual who has confirmed influenza.,vaccination is the preferred method of routine prophylaxis against infection with influenza virus.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - baloxavir marboxil, quantity: 80 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; microcrystalline cellulose; povidone; sodium stearylfumarate; purified talc; hypromellose; titanium dioxide - treatment of influenza,xofluza is indicated for the treatment of uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours and who are:,? otherwise healthy, or,? at high risk of developing influenza complications.,prophylaxis of influenza,xofluza is indicated for the post-exposure prophylaxis of influenza in patients aged 12 years of age and older following contact with an individual who has confirmed influenza.,vaccination is the preferred method of routine prophylaxis against infection with influenza virus.